Michael Burkes Brophy Sells 317 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 317 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $267.99, for a total value of $84,952.83. Following the transaction, the chief financial officer owned 52,115 shares of the company’s stock, valued at $13,966,298.85. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, August 4th, Michael Burkes Brophy sold 478 shares of Natera stock. The shares were sold at an average price of $274.22, for a total value of $131,077.16.
• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The shares were sold at an average price of $249.38, for a total transaction of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total transaction of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $203,703.18.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $265.38 on Friday. The company’s 50 day moving average price is $252.06 and its 200-day moving average price is $223.09. Natera, Inc. has a 52-week low of $136.21 and a 52-week high of $288.04. The company has a market capitalization of $38.01 billion, a P/E ratio of -162.81 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period in the prior year, the company posted ($0.74) earnings per share. Natera’s revenue for the quarter was up 37.7% compared to the same quarter last year. Analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Wellington Management Group LLP grew its holdings in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after buying an additional 2,420,263 shares in the last quarter. State Street Corp raised its position in Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the last quarter. Coatue Management LLC raised its position in Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Natera by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock valued at $596,078,000 after purchasing an additional 11,689 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year and well above analysts’ $661.2 million estimate. Its adjusted loss of $0.47 per share was also slightly better than the $0.49 consensus and improved from a $0.74 loss a year earlier. Gross margin increased to 64.5% from 63.4%. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.9 billion, ahead of the roughly $2.8 billion analyst consensus. The outlook reinforces expectations for continued demand across Natera’s reproductive health, oncology, and transplant testing businesses.
• Positive Sentiment: Natera submitted its Signatera molecular residual disease test to Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer. Regulatory approval could expand Signatera’s international addressable market and create another source of oncology revenue. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and other executives sold shares totaling about $2.0 million. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding from vested equity awards, and the executives retained substantial holdings, limiting their value as a negative confidence signal.
• Negative Sentiment: Natera remains unprofitable, reporting a negative net margin and return on equity. Although the quarterly loss narrowed year over year, investors may be focused on the company’s path to sustained earnings, particularly after the stock’s sharp rise and proximity to its 52-week high.

Analyst Ratings Changes

Several research firms have recently weighed in on NTRA. William Blair began coverage on Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating for the company. Guggenheim upped their target price on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, June 29th. UBS Group set a $260.00 target price on Natera in a research note on Wednesday, June 24th. Morgan Stanley lifted their target price on Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Sanford C. Bernstein started coverage on Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.